Work

AGITG NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx368.042

Authors: M. Khasraw, M.S. Hofman, L. Chantrill, N. Pavlakis, V. Gebski, A.J. Gill, B. Markman, S. Yip, E. Gibbs, C. Karapetis, S.F. Wong, D.T. Ransom, M. Michael, K. Wilson, J. Simes, L. Lipton

Institutions: The University of Sydney, The University of Melbourne, Peter MacCallum Cancer Centre, St Vincent's Hospital Sydney, The Kinghorn Cancer Centre, Northern Cancer Institute, Royal North Shore Hospital, Monash Health, Flinders Medical Centre, Barwon Health, Geelong Hospital, Fiona Stanley Hospital, The Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research, Footscray Hospital, Western Hospital

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2761639580

FWCI:

Cites:

Cited by:

Related to: 10